Helixgate

Helixgate

Uncategorized

Regeneron basks in first gene therapy approval as Dupixent, Eylea carry robust Q1 earnings

Published

on

Regeneron hauled in $3.6 billion during the first quarter of 2026, as analysts homed in on a slight Eylea HD miss and key upcoming readouts, including for LAG3 candidate fianlimab in metastatic melanoma.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

Federal appeals court blocks mailing of abortion pill mifepristone

Published

on

A federal appeals court has restricted access to one of the most common means of abortion in the U.S. by blocking the mailing of mifepristone prescriptions.

Friday’s unanimous ruling from a three-judge panel of the New Orleans-based 5th U.S. Circuit Court of Appeals is requiring that the abortion pill be distributed only in person and at clinics, overruling regulations set by the federal Food and Drug Administration.

Read the rest…

Continue Reading

Uncategorized

Bristol Myers’ pivotal year; Should AI be swinging bigger?; and more

Bristol Myers’ pivotal year; Should AI be swinging bigger?; and more

Published

on

Welcome back to Endpoints Weekly! The last week of April brought a downpour of news as several pharma companies reported their first-quarter earnings. Max Gelman took a close look at a make-or-break moment for Bristol …​ ​Read More

Continue Reading

Uncategorized

Arvinas’ ‘Protac’ breast cancer drug cleared by FDA

Published

on

Known as Veppanu, the drug is the first of its kind to get to market. But Arvinas and partner Pfizer are still searching for a new partner to sell it.

Continue Reading
Advertisement

Trending